부산대학교 도서관

Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report Everolimus is widely used to prevent rejection after solid organ transplantation; however, adjustment of its dose is difficult due to its narrow therapeutic range.[1] Everolimus is primarily metabolised by cytochrome P450 (CYP) 3A and is hence susceptible to drug-drug interactions.[1] Clotrimazole troche is an azole antifungal drug, which gradually dissolves in the oral cavity. Everolimus is metabolised by CYP3A in the liver and intestines.[6] Although the clotrimazole bioavailability was low, clotrimazole troche may have affected everolimus bioavailability by inhibiting intestinal first-pass metabolism. Clotrimazole troche may inhibit everolimus metabolism, resulting in reduced everolimus bioavailability (via increased metabolism) following clotrimazole discontinuation. [Extracted from the article]